Study Finds GLP-1 Meds, such as Ozempic, Wegovy, Can Also Help the Kidneys

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 26, 2024.

By Ernie Mundell HealthDay Reporter

TUESDAY, Nov. 26, 2024 -- The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also shield your kidneys from harm.

In the largest study to date on the effects of the drugs on the kidneys, researchers found GLP-1s help the protect the organs in people with or without diabetes.

GLP-1s include blockbuster diabetes medicines such as Ozempic and its weight-loss spinoff, Wegovy.

“This is the first study to show a clear benefit of GLP-1 receptor agonists on kidney failure or end-stage kidney disease," said study lead author Dr. Sunil Badve, a kidney specialist and professorial fellow at The George Institute for Global Health in Sydney, Australia.

The study suggests that GLP-1s "have a key role in kidney-protective and heart-protective treatment for patients with common medical conditions like type 2 diabetes, overweight or obesity with cardiovascular disease, or chronic kidney disease," he said in a news release.

The research was published Nov. 25 in The Lancet Diabetes & Endocrinology.

Badve and colleagues conducted what's called a meta-analysis -- a large review of data from multiple studies, in this case 11 large-scale clinical trials of GLP-1s involving more than 85,000 people in all.

Close to 68,000 had type 2 diabetes, while just over 17,600 were overweight or obese with heart disease but did not have type 2 diabetes.

The GLP-1 medicines taken during the trials included semaglutide (Ozempic or Wegovy), dulaglutide (Trulicity) and liraglutide (Victoza).

Kidney health improved among people taking the drugs, the study found.

For example, use of a GLP-1 cut a patient's odds of kidney failure by 16% and a worsening of their kidney function by 22%, Budve and team reported. These improvements were defined as "a drop in estimated glomerular filtration rate -- a measure of how much blood the kidneys filter clean every minute -- of at least 50%," according to the news release.

“These results are particularly important for patients with chronic kidney disease," Badve said. "It is a progressive condition eventually leading to kidney failure requiring dialysis or kidney transplantation and is associated with premature death, mostly from heart disease. It has a significant impact on patients’ quality of life and incurs substantial healthcare costs."

People's hearts benefited, too: Use of a GLP-1 cut a person's odds for a combination outcome of heart-related death, non-fatal heart attacks and non-fatal strokes by 14%, compared to folks taking a placebo.

In fact, GLP-1 use was linked to a 13% reduction in a person's risk of premature death from any cause, the research showed.

"Our study will have a major impact on clinical guidelines for the management of chronic kidney disease and cardiovascular disease in people with and without diabetes," said study co-author Dr. Vlado Perkovic, also a professorial fellow at The George Institute.

Sources

  • George Institute for Global Health, news release, Nov. 25, 2024

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2024-11-27 06:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords